Immunoprotein-Mediated siRNA Delivery

Molecular Pharmaceutics

Volumn 14, Issue 5, 2017, Pages 1339-1351

  Bäumer, Nicole ^a   Berdel, Wolfgang E ^a   Bäumer, Sebastian ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

bioconjugate therapeutics; siRNA; specificity; stabilization; therapeutic antibodies

Indexed keywords

ANTIBODY; DRUG CARRIER; IMMUNOGLOBULIN; IMMUNOLIPOSOME; LIGAND; NANOCARRIER; PEPTIDE; PROTAMINE; RECEPTOR; SMALL INTERFERING RNA; IMMUNOGLOBULIN F(AB) FRAGMENT;

CONJUGATE; CONJUGATION; ENDOCYTOSIS; HUMAN; INTRACELLULAR TRANSPORT; LIPOSOMAL DELIVERY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA TRANSPORT; RNAI THERAPEUTICS; TARGET CELL; CHEMISTRY; RNA INTERFERENCE;

ANTIBODIES; IMMUNOGLOBULIN FAB FRAGMENTS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85018404607     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b01039     Document Type: Review

References (108)

1. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 1998, 391, 806-811 10.1038/35888
2. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W. S.; Khvorova, A. Rational siRNA design for RNA interference Nat. Biotechnol. 2004, 22, 326-330 10.1038/nbt936
3. Parsons, B. D.; Schindler, A.; Evans, D. H.; Foley, E. A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay PLoS One 2009, 4, e8471 10.1371/journal.pone.0008471
4. Surendranath, V.; Theis, M.; Habermann, B. H.; Buchholz, F. Designing efficient and specific endoribonuclease-prepared siRNAs Methods Mol. Biol. 2013, 942, 193-204 10.1007/978-1-62703-119-6_11
5. Kittler, R.; Surendranath, V.; Heninger, A. K.; Slabicki, M.; Theis, M.; Putz, G.; Franke, K.; Caldarelli, A.; Grabner, H.; Kozak, K.; Wagner, J.; Rees, E.; Korn, B.; Frenzel, C.; Sachse, C.; Sonnichsen, B.; Guo, J.; Schelter, J.; Burchard, J.; Linsley, P. S.; Jackson, A. L.; Habermann, B.; Buchholz, F. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies Nat. Methods 2007, 4, 337-344 10.1038/nmeth1025
6. Bobbin, M. L.; Rossi, J. J. RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu. Rev. Pharmacol. Toxicol. 2016, 56, 103-122 10.1146/annurev-pharmtox-010715-103633
7. Kaiser, P. K.; Symons, R. C.; Shah, S. M.; Quinlan, E. J.; Tabandeh, H.; Do, D. V.; Reisen, G.; Lockridge, J. A.; Short, B.; Guerciolini, R.; Nguyen, Q. D. Sirna-027 Study Investigators RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027 Am. J. Ophthalmol. 2010, 150, 33-39.e2 10.1016/j.ajo.2010.02.006
8. Solano, E. C.; Kornbrust, D. J.; Beaudry, A.; Foy, J. W.; Schneider, D. J.; Thompson, J. D. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection Nucleic Acid Ther. 2014, 24, 258-266 10.1089/nat.2014.0489
9. DeVincenzo, J.; Lambkin-Williams, R.; Wilkinson, T.; Cehelsky, J.; Nochur, S.; Walsh, E.; Meyers, R.; Gollob, J.; Vaishnaw, A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 8800-8805 10.1073/pnas.0912186107
10. Tabernero, J.; Shapiro, G. I.; LoRusso, P. M.; Cervantes, A.; Schwartz, G. K.; Weiss, G. J.; Paz-Ares, L.; Cho, D. C.; Infante, J. R.; Alsina, M.; Gounder, M. M.; Falzone, R.; Harrop, J.; White, A. C.; Toudjarska, I.; Bumcrot, D.; Meyers, R. E.; Hinkle, G.; Svrzikapa, N.; Hutabarat, R. M.; Clausen, V. A.; Cehelsky, J.; Nochur, S. V.; Gamba-Vitalo, C.; Vaishnaw, A. K.; Sah, D. W.; Gollob, J. A.; Burris, H. A., 3rd First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement Cancer Discovery 2013, 3, 406-417 10.1158/2159-8290.CD-12-0429
11. Coelho, T.; Adams, D.; Silva, A.; Lozeron, P.; Hawkins, P. N.; Mant, T.; Perez, J.; Chiesa, J.; Warrington, S.; Tranter, E.; Munisamy, M.; Falzone, R.; Harrop, J.; Cehelsky, J.; Bettencourt, B. R.; Geissler, M.; Butler, J. S.; Sehgal, A.; Meyers, R. E.; Chen, Q.; Borland, T.; Hutabarat, R. M.; Clausen, V. A.; Alvarez, R.; Fitzgerald, K.; Gamba-Vitalo, C.; Nochur, S. V.; Vaishnaw, A. K.; Sah, D. W.; Gollob, J. A.; Suhr, O. B. Safety and efficacy of RNAi therapy for transthyretin amyloidosis N. Engl. J. Med. 2013, 369, 819-829 10.1056/NEJMoa1208760
12. Nemunaitis, J.; Barve, M.; Orr, D.; Kuhn, J.; Magee, M.; Lamont, J.; Bedell, C.; Wallraven, G.; Pappen, B. O.; Roth, A.; Horvath, S.; Nemunaitis, D.; Kumar, P.; Maples, P. B.; Senzer, N. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver Oncology 2014, 87, 21-29 10.1159/000360993
13. Zorde Khvalevsky, E.; Gabai, R.; Rachmut, I. H.; Horwitz, E.; Brunschwig, Z.; Orbach, A.; Shemi, A.; Golan, T.; Domb, A. J.; Yavin, E.; Giladi, H.; Rivkin, L.; Simerzin, A.; Eliakim, R.; Khalaileh, A.; Hubert, A.; Lahav, M.; Kopelman, Y.; Goldin, E.; Dancour, A.; Hants, Y.; Arbel-Alon, S.; Abramovitch, R.; Shemi, A.; Galun, E. Mutant KRAS is a druggable target for pancreatic cancer Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 20723-20728 10.1073/pnas.1314307110
14. Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 15549-15554 10.1073/pnas.0707461104
15. Yu, B.; Zhao, X.; Lee, L. J.; Lee, R. J. Targeted delivery systems for oligonucleotide therapeutics AAPS J. 2009, 11, 195-203 10.1208/s12248-009-9096-1
16. Srinivasarao, M.; Galliford, C. V.; Low, P. S. Principles in the design of ligand-targeted cancer therapeutics and imaging agents Nat. Rev. Drug Discovery 2015, 14, 203-219 10.1038/nrd4519
17. Vergote, I.; Leamon, C. P. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors Ther. Adv. Med. Oncol. 2015, 7, 206-218 10.1177/1758834015584763
18. Stucke-Ring, J.; Ronnacker, J.; Brand, C.; Holtke, C.; Schliemann, C.; Kessler, T.; Schmidt, L. H.; Harrach, S.; Mantke, V.; Hintelmann, H.; Hartmann, W.; Wardelmann, E.; Lenz, G.; Wunsch, B.; Muller-Tidow, C.; Mesters, R. M.; Schwoppe, C.; Berdel, W. E. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction Oncotarget 2016, 10.18632/oncotarget.12559
19. Brand, C.; Schliemann, C.; Ring, J.; Kessler, T.; Baumer, S.; Angenendt, L.; Mantke, V.; Ross, R.; Hintelmann, H.; Spieker, T.; Wardelmann, E.; Mesters, R. M.; Berdel, W. E.; Schwoppe, C. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor Oncotarget 2016, 7, 6774-6789
20. Bieker, R.; Kessler, T.; Schwoppe, C.; Padro, T.; Persigehl, T.; Bremer, C.; Dreischaluck, J.; Kolkmeyer, A.; Heindel, W.; Mesters, R. M.; Berdel, W. E. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience Blood 2009, 113, 5019-5027 10.1182/blood-2008-04-150318
21. Dreischaluck, J.; Schwoppe, C.; Spieker, T.; Kessler, T.; Tiemann, K.; Liersch, R.; Schliemann, C.; Kreuter, M.; Kolkmeyer, A.; Hintelmann, H.; Mesters, R. M.; Berdel, W. E. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile Int. J. Oncol. 2010, 37, 1389-1397
22. Bolhassani, A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer Biochim. Biophys. Acta, Rev. Cancer 2011, 1816, 232-246 10.1016/j.bbcan.2011.07.006
23. Tian, H.; Lin, L.; Chen, J.; Chen, X.; Park, T. G.; Maruyama, A. RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers J. Controlled Release 2011, 155, 47-53 10.1016/j.jconrel.2011.01.025
24. Corti, A.; Curnis, F.; Rossoni, G.; Marcucci, F.; Gregorc, V. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example BioDrugs 2013, 27, 591-603 10.1007/s40259-013-0048-z
25. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2002, 2, 750-63 10.1038/nrc903
26. Ren, Y.; Hauert, S.; Lo, J. H.; Bhatia, S. N. Identification and characterization of receptor-specific peptides for siRNA delivery ACS Nano 2012, 6, 8620-8631 10.1021/nn301975s
27. Jarver, P.; Coursindel, T.; Andaloussi, S. E.; Godfrey, C.; Wood, M. J.; Gait, M. J. Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA Mol. Ther.--Nucleic Acids 2012, 1, e27 10.1038/mtna.2012.18
28. Ehrlich, P. Collected Studies on Immunity; John Wiley & Sons: New York, 1906.
29. Weiner, L. M.; Surana, R.; Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 2010, 10, 317-327 10.1038/nri2744
30. Casi, G.; Neri, D. Antibody-drug conjugates: basic concepts, examples and future perspectives J. Controlled Release 2012, 161, 422-428 10.1016/j.jconrel.2012.01.026
31. Weiner, G. J. Building better monoclonal antibody-based therapeutics Nat. Rev. Cancer 2015, 15, 361-370 10.1038/nrc3930
32. Lambert, J. M. Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 2012, 76, 248 10.1111/bcp.12044
33. Singer, H.; Kellner, C.; Lanig, H.; Aigner, M.; Stockmeyer, B.; Oduncu, F.; Schwemmlein, M.; Stein, C.; Mentz, K.; Mackensen, A.; Fey, G. H. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16 J. Immunother. 2010, 33, 599-608 10.1097/CJI.0b013e3181dda225
34. Pule, M. A.; Savoldo, B.; Myers, G. D.; Rossig, C.; Russell, H. V.; Dotti, G.; Huls, M. H.; Liu, E.; Gee, A. P.; Mei, Z.; Yvon, E.; Weiss, H. L.; Liu, H.; Rooney, C. M.; Heslop, H. E.; Brenner, M. K. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Nat. Med. 2008, 14, 1264-1270 10.1038/nm.1882
35. Bargou, R.; Leo, E.; Zugmaier, G.; Klinger, M.; Goebeler, M.; Knop, S.; Noppeney, R.; Viardot, A.; Hess, G.; Schuler, M.; Einsele, H.; Brandl, C.; Wolf, A.; Kirchinger, P.; Klappers, P.; Schmidt, M.; Riethmuller, G.; Reinhardt, C.; Baeuerle, P. A.; Kufer, P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 2008, 321, 974-977 10.1126/science.1158545
36. Palanca-Wessels, M. C.; Booth, G. C.; Convertine, A. J.; Lundy, B. B.; Berguig, G. Y.; Press, M. F.; Stayton, P. S.; Press, O. W. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells Oncotarget 2016, 7, 9561-9575
37. Bäumer, N.; Appel, N.; Terheyden, L.; Buchholz, F.; Rossig, C.; Muller-Tidow, C.; Berdel, W. E.; Baumer, S. Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown Nat. Protoc. 2016, 11, 22-36 10.1038/nprot.2015.137
38. Bäumer, S.; Bäumer, N.; Appel, N.; Terheyden, L.; Fremerey, J.; Schelhaas, S.; Wardelmann, E.; Buchholz, F.; Berdel, W. E.; Muller-Tidow, C. Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer Clin. Cancer Res. 2015, 21 ( 6 ) 1383-94 10.1158/1078-0432.CCR-13-2017
39. Song, E.; Zhu, P.; Lee, S. K.; Chowdhury, D.; Kussman, S.; Dykxhoorn, D. M.; Feng, Y.; Palliser, D.; Weiner, D. B.; Shankar, P.; Marasco, W. A.; Lieberman, J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 2005, 23, 709-17 10.1038/nbt1101
40. Feuring-Buske, M.; Buske, C.; Unterhalt, M.; Hiddemann, W. Recent advances in antigen-targeted therapy in non-Hodgkin’s lymphoma Ann. Hematol. 2000, 79, 167-174 10.1007/s002770050575
41. Kies, M. S.; Harari, P. M. Cetuximab (Imclone/Merck/Bristol-Myers Squibb) Curr. Opin. Investig Drugs 2002, 3, 1092-1100
42. Langerak, A.; River, G.; Mitchell, E.; Cheema, P.; Shing, M. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports Clin. Colorectal Cancer 2009, 8, 49-54 10.3816/CCC.2009.n.008
43. Cioffi, M.; Dorado, J.; Baeuerle, P. A.; Heeschen, C. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells Clin. Cancer Res. 2012, 18, 465-474 10.1158/1078-0432.CCR-11-1270
44. Feucht, J.; Kayser, S.; Gorodezki, D.; Hamieh, M.; Doring, M.; Blaeschke, F.; Schlegel, P.; Bosmuller, H.; Quintanilla-Fend, L.; Ebinger, M.; Lang, P.; Handgretinger, R.; Feuchtinger, T. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts Oncotarget 2016, 10.18632/oncotarget.12357
45. Castaigne, S.; Pautas, C.; Terre, C.; Raffoux, E.; Bordessoule, D.; Bastie, J. N.; Legrand, O.; Thomas, X.; Turlure, P.; Reman, O.; de Revel, T.; Gastaud, L.; de Gunzburg, N.; Contentin, N.; Henry, E.; Marolleau, J. P.; Aljijakli, A.; Rousselot, P.; Fenaux, P.; Preudhomme, C.; Chevret, S.; Dombret, H. Acute Leukemia French Association Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Lancet 2012, 379, 1508-1516 10.1016/S0140-6736(12)60485-1
46. Gleissner, B.; Schlenk, R.; Bornhauser, M.; Berdel, W. E. Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials Oncol. Res. Treat. 2007, 30, 657-662 10.1159/000109956
47. Hoelzer, D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia Curr. Opin. Oncol. 2013, 25, 701-706 10.1097/CCO.0000000000000009
48. Rizzieri, D. Zevalin((R)) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? Crit. Rev. Oncol. Hematol. 2016, 105, 5-17 10.1016/j.critrevonc.2016.07.008
49. Ramsey, S. D.; Nademanee, A.; Masszi, T.; Holowiecki, J.; Abidi, M.; Chen, A.; Stiff, P.; Viviani, S.; Sweetenham, J. W.; Radford, J.; Zhu, Y.; Bonthapally, V.; Thomas, E.; Richhariya, A.; Hunder, N. N.; Walewski, J.; Moskowitz, C. H. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma Br. J. Haematol. 2016, 175, 860 10.1111/bjh.14316
50. Song, E.; Lee, S. K.; Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P.; Lieberman, J. RNA interference targeting Fas protects mice from fulminant hepatitis Nat. Med. 2003, 9, 347-351 10.1038/nm828
51. DeVincenzo, J.; Cehelsky, J. E.; Alvarez, R.; Elbashir, S.; Harborth, J.; Toudjarska, I.; Nechev, L.; Murugaiah, V.; Van Vliet, A.; Vaishnaw, A. K.; Meyers, R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV) Antiviral Res. 2008, 77, 225-231 10.1016/j.antiviral.2007.11.009
52. Christie, R. J.; Matsumoto, Y.; Miyata, K.; Nomoto, T.; Fukushima, S.; Osada, K.; Halnaut, J.; Pittella, F.; Kim, H. J.; Nishiyama, N.; Kataoka, K. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection ACS Nano 2012, 6, 5174-5189 10.1021/nn300942b
53. Hauser, P. V.; Pippin, J. W.; Kaiser, C.; Krofft, R. D.; Brinkkoetter, P. T.; Hudkins, K. L.; Kerjaschki, D.; Reiser, J.; Alpers, C. E.; Shankland, S. J. Novel siRNA delivery system to target podocytes in vivo PLoS One 2010, 5, e9463 10.1371/journal.pone.0009463
54. Choi, Y. S.; Lee, J. Y.; Suh, J. S.; Kwon, Y. M.; Lee, S. J.; Chung, J. K.; Lee, D. S.; Yang, V. C.; Chung, C. P.; Park, Y. J. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine Biomaterials 2009, 31, 1429-43 10.1016/j.biomaterials.2009.11.001
55. Kumar, P.; Ban, H. S.; Kim, S. S.; Wu, H.; Pearson, T.; Greiner, D. L.; Laouar, A.; Yao, J.; Haridas, V.; Habiro, K.; Yang, Y. G.; Jeong, J. H.; Lee, K. Y.; Kim, Y. H.; Kim, S. W.; Peipp, M.; Fey, G. H.; Manjunath, N.; Shultz, L. D.; Lee, S. K.; Shankar, P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice Cell 2008, 134, 577-86 10.1016/j.cell.2008.06.034
56. Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche, V.; Fisch, G.; Dames, S.; Loffler, K.; Fechtner, M.; Arnold, W.; Giese, K.; Klippel, A.; Kaufmann, J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium Gene Ther. 2006, 13, 1222-1234 10.1038/sj.gt.3302777
57. Landen, C. N., Jr; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M. T.; Lopez-Berestein, G.; Sood, A. K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery Cancer Res. 2005, 65, 6910-6918 10.1158/0008-5472.CAN-05-0530
58. Navarro, G.; Sawant, R. R.; Biswas, S.; Essex, S.; Tros de Ilarduya, C.; Torchilin, V. P. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells Nanomedicine (London, U. K.) 2012, 7, 65-78 10.2217/nnm.11.93
59. Sun, T. M.; Du, J. Z.; Yan, L. F.; Mao, H. Q.; Wang, J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery Biomaterials 2008, 29, 4348-4355 10.1016/j.biomaterials.2008.07.036
60. Navarro, G.; Sawant, R. R.; Essex, S.; Tros de Ilarduya, C.; Torchilin, V. P. Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery Drug Delivery Transl. Res. 2011, 1, 25-33 10.1007/s13346-010-0004-0
61. Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo Gene Ther. 2005, 12, 461-466 10.1038/sj.gt.3302425
62. Philipp, A.; Zhao, X.; Tarcha, P.; Wagner, E.; Zintchenko, A. Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery Bioconjugate Chem. 2009, 20, 2055-2061 10.1021/bc9001536
63. Fraley, R.; Subramani, S.; Berg, P.; Papahadjopoulos, D. Introduction of liposome-encapsulated SV40 DNA into cells J. Biol. Chem. 1980, 255, 10431-10435
64. Schaefer-Ridder, M.; Wang, Y.; Hofschneider, P. H. Liposomes as gene carriers: efficient transformation of mouse L cells by thymidine kinase gene Science 1982, 215, 166-168 10.1126/science.7053567
65. Zhang, Y.; Zhang, Y. F.; Bryant, J.; Charles, A.; Boado, R. J.; Pardridge, W. M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer Clin. Cancer Res. 2004, 10, 3667-3677 10.1158/1078-0432.CCR-03-0740
66. Gao, J.; Yu, Y.; Zhang, Y.; Song, J.; Chen, H.; Li, W.; Qian, W.; Deng, L.; Kou, G.; Chen, J.; Guo, Y. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma Biomaterials 2012, 33, 270-282 10.1016/j.biomaterials.2011.09.035
67. Chen, Y.; Zhu, X.; Zhang, X.; Liu, B.; Huang, L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy Mol. Ther. 2010, 18, 1650-1656 10.1038/mt.2010.136
68. Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 2010, 464, 1067-1070 10.1038/nature08956
69. Hu-Lieskovan, S.; Heidel, J. D.; Bartlett, D. W.; Davis, M. E.; Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma Cancer Res. 2005, 65, 8984-8992 10.1158/0008-5472.CAN-05-0565
70. Yao, Y. D.; Sun, T. M.; Huang, S. Y.; Dou, S.; Lin, L.; Chen, J. N.; Ruan, J. B.; Mao, C. Q.; Yu, F. Y.; Zeng, M. S.; Zang, J. Y.; Liu, Q.; Su, F. X.; Zhang, P.; Lieberman, J.; Wang, J.; Song, E. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis Sci. Transl. Med. 2012, 4, 130ra48 10.1126/scitranslmed.3003601
71. Peer, D.; Zhu, P.; Carman, C. V.; Lieberman, J.; Shimaoka, M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 4095-4100 10.1073/pnas.0608491104
72. Graham, F. L.; van der Eb, A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA Virology 1973, 52, 456-467 10.1016/0042-6822(73)90341-3
73. Rezaee, M.; Oskuee, R. K.; Nassirli, H.; Malaekeh-Nikouei, B. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems J. Controlled Release 2016, 236, 1-14 10.1016/j.jconrel.2016.06.023
74. Varkouhi, A. K.; Scholte, M.; Storm, G.; Haisma, H. J. Endosomal escape pathways for delivery of biologicals J. Controlled Release 2011, 151, 220-228 10.1016/j.jconrel.2010.11.004
75. Veronese, F. M.; Pasut, G. PEGylation, successful approach to drug delivery Drug Discovery Today 2005, 10, 1451-1458 10.1016/S1359-6446(05)03575-0
76. Chono, S.; Li, S. D.; Conwell, C. C.; Huang, L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor J. Controlled Release 2008, 131, 64-69 10.1016/j.jconrel.2008.07.006
77. Yang, C.; Wei, W. The miRNA expression profile of the uveal melanoma Sci. China: Life Sci. 2011, 54, 351-358 10.1007/s11427-011-4149-y
78. Gao, J.; Sun, J.; Li, H.; Liu, W.; Zhang, Y.; Li, B.; Qian, W.; Wang, H.; Chen, J.; Guo, Y. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing Biomaterials 2010, 31, 2655-2664 10.1016/j.biomaterials.2009.11.112
79. Gao, J.; Liu, W.; Xia, Y.; Li, W.; Sun, J.; Chen, H.; Li, B.; Zhang, D.; Qian, W.; Meng, Y.; Deng, L.; Wang, H.; Chen, J.; Guo, Y. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes Biomaterials 2011, 32, 3459-3470 10.1016/j.biomaterials.2011.01.034
80. Deng, L.; Zhang, Y.; Ma, L.; Jing, X.; Ke, X.; Lian, J.; Zhao, Q.; Yan, B.; Zhang, J.; Yao, J.; Chen, J. Comparison of anti-EGFR-Fab’ conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells Int. J. Nanomed. 2013, 8, 3271-3283 10.2147/IJN.S47597
81. Khantasup, K.; Kopermsub, P.; Chaichoun, K.; Dharakul, T. Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection Antimicrob. Agents Chemother. 2014, 58, 2816-2824 10.1128/AAC.02768-13
82. Heidel, J. D.; Yu, Z.; Liu, J. Y.; Rele, S. M.; Liang, Y.; Zeidan, R. K.; Kornbrust, D. J.; Davis, M. E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 5715-5721 10.1073/pnas.0701458104
83. Zuckerman, J. E.; Gritli, I.; Tolcher, A.; Heidel, J. D.; Lim, D.; Morgan, R.; Chmielowski, B.; Ribas, A.; Davis, M. E.; Yen, Y. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 11449-11454 10.1073/pnas.1411393111
84. Hansen, B.; Linde, S.; Kolendorf, K.; Jensen, F. Absorption of protamine-insulin in diabetic patients. I. Preparation and characterization of protamine-125I-insulin Horm. Metab. Res. 1979, 11, 85-90 10.1055/s-0028-1092685
85. Liu, B. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA Briefings Funct. Genomics Proteomics 2007, 6, 112-9 10.1093/bfgp/elm015
86. He, H.; Ye, J.; Liu, E.; Liang, Q.; Liu, Q.; Yang, V. C. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide J. Controlled Release 2014, 193, 63-73 10.1016/j.jconrel.2014.05.056
87. Ayene, I. S.; Ford, L. P.; Koch, C. J. Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation Mol. Cancer Ther. 2005, 4, 529-536 10.1158/1535-7163.MCT-04-0130
88. Spicer, C. D.; Davis, B. G. Selective chemical protein modification Nat. Commun. 2014, 5, 4740 10.1038/ncomms5740
89. Bernardes, G. J.; Steiner, M.; Hartmann, I.; Neri, D.; Casi, G. Site-specific chemical modification of antibody fragments using traceless cleavable linkers Nat. Protoc. 2013, 8, 2079-2089 10.1038/nprot.2013.121
90. Liu, H.; May, K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function MAbs 2012, 4, 17-23 10.4161/mabs.4.1.18347
91. Xia, C. F.; Boado, R. J.; Pardridge, W. M. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology Mol. Pharmaceutics 2009, 6, 747-751 10.1021/mp800194y
92. Sugo, T.; Terada, M.; Oikawa, T.; Miyata, K.; Nishimura, S.; Kenjo, E.; Ogasawara-Shimizu, M.; Makita, Y.; Imaichi, S.; Murata, S.; Otake, K.; Kikuchi, K.; Teratani, M.; Masuda, Y.; Kamei, T.; Takagahara, S.; Ikeda, S.; Ohtaki, T.; Matsumoto, H. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles J. Controlled Release 2016, 237, 1-13 10.1016/j.jconrel.2016.06.036
93. Boussif, O.; Lezoualc’h, F.; Zanta, M. A.; Mergny, M. D.; Scherman, D.; Demeneix, B.; Behr, J. P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 7297-7301 10.1073/pnas.92.16.7297
94. Kim, T. I.; Kim, S. W. Bioreducible polymers for gene delivery React. Funct. Polym. 2011, 71, 344-349 10.1016/j.reactfunctpolym.2010.11.016
95. Ou, M.; Xu, R.; Kim, S. H.; Bull, D. A.; Kim, S. W. A family of bioreducible poly(disulfide amine)s for gene delivery Biomaterials 2009, 30, 5804-5814 10.1016/j.biomaterials.2009.06.050
96. Schmid, J. A. The acidic environment in endocytic compartments Biochem. J. 1994, 303 ( Pt 2 ) 679-680 10.1042/bj3030679
97. Wyman, T. B.; Nicol, F.; Zelphati, O.; Scaria, P. V.; Plank, C.; Szoka, F. C., Jr Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers Biochemistry 1997, 36, 3008-3017 10.1021/bi9618474
98. Lee, H.; Jeong, J. H.; Park, T. G. A new gene delivery formulation of polyethylenimine/DNA complexes coated with PEG conjugated fusogenic peptide J. Controlled Release 2001, 76, 183-192 10.1016/S0168-3659(01)00426-6
99. Min, S. H.; Lee, D. C.; Lim, M. J.; Park, H. S.; Kim, D. M.; Cho, C. W.; Yoon, D. Y.; Yeom, Y. I. A composite gene delivery system consisting of polyethylenimine and an amphipathic peptide KALA J. Gene Med. 2006, 8, 1425-1434 10.1002/jgm.973
100. Parente, R. A.; Nir, S.; Szoka, F. C., Jr Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA Biochemistry 1990, 29, 8720-8728 10.1021/bi00489a031
101. Sasaki, K.; Kogure, K.; Chaki, S.; Nakamura, Y.; Moriguchi, R.; Hamada, H.; Danev, R.; Nagayama, K.; Futaki, S.; Harashima, H. An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives Anal. Bioanal. Chem. 2008, 391, 2717-2727 10.1007/s00216-008-2012-1
102. Oliveira, S.; van Rooy, I.; Kranenburg, O.; Storm, G.; Schiffelers, R. M. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes Int. J. Pharm. 2007, 331, 211-214 10.1016/j.ijpharm.2006.11.050
103. Mastrobattista, E.; Koning, G. A.; van Bloois, L.; Filipe, A. C.; Jiskoot, W.; Storm, G. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins J. Biol. Chem. 2002, 277, 27135-27143 10.1074/jbc.M200429200
104. Jiang, X.; Lok, M. C.; Hennink, W. E. Degradable-brushed pHEMA-pDMAEMA synthesized via ATRP and click chemistry for gene delivery Bioconjugate Chem. 2007, 18, 2077-2084 10.1021/bc0701186
105. Carr, J. A.; Silverman, N. The heparin-protamine interaction. A review J. Cardiovasc. Surg. (Torino) 1999, 40, 659-666
106. Cornetta, K.; Anderson, W. F. Protamine sulfate as an effective alternative to Polybrene in retroviral-mediated gene-transfer: implications for human gene therapy J. Virol. Methods 1989, 23, 187-194 10.1016/0166-0934(89)90132-8
107. Sorgi, F. L.; Bhattacharya, S.; Huang, L. Protamine sulfate enhances lipid-mediated gene transfer Gene Ther. 1997, 4, 961-968 10.1038/sj.gt.3300484
108. Tabrizi, M.; Bornstein, G. G.; Suria, H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease AAPS J. 2010, 12, 33-43 10.1208/s12248-009-9157-5